Thera-SAbDab

DUVORTUXIZUMAB

>   Structural Summary
TherapeuticDuvortuxizumab
Target 1CD19
Heavy Chain 1QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVGWIRQPPGKALEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVFLTMTNMDPVDTATYYCARMELWSYYFDYWGQGTTVTVSS
Light Chain 1ENVLTQSPATLSVTPGEKATITCRASQSVSYMHWYQQKPGQAPRLLIYDASNRASGVPSRFSGSGSGTDHTLTISSLEAEDAATYYCFQGSVYPFTFGQGTKLEIK
100% seqID Fv 1 StructureNone
99% seqID Fv 1 StructureNone
95-98% seqID Fv 1 StructureNone
Target 2CD3E
Heavy Chain 2EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS
Light Chain 2QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPWTPARFSGSLLGGKAALTITGAQAEDEADYYCALWYSNLWVFGGGTKLTVL
100% seqID Fv 2 StructureNone
99% seqID Fv 2 StructureNone
95-98% seqID Fv 2 StructureNone
>   Metadata
FormatBispecific scFv with Crossover
Isotypena
Highest Clinical Trial (Jan '20)Phase-I
Estimated Status (Jan '20)Discontinued
Recorded Developmental TechnologyDual-Affinity Re-Targeting Technology
INN Year Proposed2016
INN Year Recommended2017
Companies InvolvedJanssen Biotech, MacroGenics
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedDiffuse large B cell lymphoma, Follicular lymphoma, Non-Hodgkin's lymphoma, Precursor B-cell lymphoblastic leukaemia-lymphoma
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]